Labels use the same three-part definition when they describe a medicine's heart indication; the Wegovy label, for example, approves it to reduce the risk of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.1
Why trials combine events
Each event on its own is relatively rare, even in people at high risk. Combining them gives a trial enough events to reach an answer in a few years. The cost is that a result on MACE can be driven by one part more than the others. In SUSTAIN 6, for example, semaglutide lowered MACE with a hazard ratio of 0.74, while cardiovascular deaths were similar in the two groups and the clearest difference was in non-fatal stroke.2 Reading the parts as well as the total is the safest way to understand any MACE result.
Three-part and four-part MACE
Most GLP-1 trials used the three-part version. ELIXA, the trial of lixisenatide in people with a recent acute coronary event, added a fourth part, hospital stays for unstable angina.3 AMPLITUDE-O counted deaths from undetermined causes together with cardiovascular deaths.4 These differences make direct comparisons between trials rough. Trials also differ in whether they enrolled only people with established heart disease, as LEADER mostly did, or also people with risk factors alone, as REWIND did, which changes how many events occur on placebo.5,6
MACE in the GLP-1 trials
| Trial, drug | MACE on drug | MACE on placebo | Hazard ratio |
|---|---|---|---|
| SELECT, semaglutide 2.4 mg | 6.5% | 8.0% | 0.80 |
| SUSTAIN 6, semaglutide | 6.6% | 8.9% | 0.74 |
| LEADER, liraglutide | 13.0% | 14.9% | 0.87 |
| REWIND, dulaglutide | 12.0% | 13.4% | 0.88 |
| Harmony Outcomes, albiglutide | 7% | 9% | 0.78 |
| AMPLITUDE-O, efpeglenatide | 7.0% | 9.2% | 0.73 |
| EXSCEL, weekly exenatide | 11.4% | 12.2% | 0.91 |
| ELIXA, lixisenatide | 13.4% | 13.2% | 1.02 |
Each trial's main report.2,3,4,5,6,7,8,9
Six of the eight trials showed fewer events on the drug; EXSCEL narrowly missed, and ELIXA found no difference. The trials enrolled different people for different lengths of time, so the percentages are not comparable across rows; the hazard ratios are a fairer guide.
How to read a hazard ratio
A hazard ratio compares the rate of events in two groups over time. A ratio of 0.8 means events happened about 20% less often on the drug; 1.0 means no difference. Each ratio comes with a confidence interval. When that interval stays below 1.0, as in SELECT, the benefit is statistically clear; when it touches 1.0, as in EXSCEL, it is not.7,9
Looking at the parts
The SELECT trial shows why the parts matter. Its MACE result, 6.5% against 8.0%, came with fatal or non-fatal heart attacks in 2.8% against 3.8%, while cardiovascular death on its own, 2.5% against 3.0%, was not a statistically clear difference.1 Trials also report outcomes beyond MACE. In LEADER, death from any cause fell from 9.6% to 8.2%; in FLOW, the kidney trial of semaglutide, it was 20% lower.5,10 Those results do not change the MACE figure, but they give a fuller picture of what the drug does.
On the labels
Several labels carry a MACE indication based on these trials: Wegovy for adults with heart disease and excess weight, and Ozempic, Victoza and Trulicity for adults with type 2 diabetes and heart disease or, for Trulicity, multiple risk factors.1,11 Our page on Ozempic and Wegovy sets out which brand is approved for what.
Sources
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 14.1. accessdata.fda.gov
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141
- Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med 2015;373:2247-2257. doi:10.1056/NEJMoa1509225
- Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (AMPLITUDE-O). N Engl J Med 2021;385:896-907. doi:10.1056/NEJMoa2108269
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. doi:10.1056/NEJMoa1603827
- Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019;394:121-130. doi:10.1016/S0140-6736(19)31149-3
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232. doi:10.1056/NEJMoa2307563
- Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes). Lancet 2018;392:1519-1529. doi:10.1016/S0140-6736(18)32261-X
- Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). N Engl J Med 2017;377:1228-1239. doi:10.1056/NEJMoa1612917
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109-121. doi:10.1056/NEJMoa2403347
- OZEMPIC injection prescribing information (FDA, revised May 2026), VICTOZA and TRULICITY prescribing information (DailyMed); section 1 of each. accessdata.fda.gov
Related analyses
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
Ozempic side effects: how common each one is by dose, and when they ease
Wegovy cost: what the pen and the pill cost with insurance, without it, and over a year
Log your doses with blood pressure and heart checkups in one place.
Open Dose Insider